Renal Cell Carcinoma

While there are reliable biomarkers to monitor disease progression and guide treatment decisions for tyrosine kinase inhibitors in renal cell carcinoma (RCC), there is a need for biomarkers for immunotherapies.

Where renal cell carcinoma spreads can have a significant impact on prognosis and treatment options for patients.

In this first part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, provides an overview of the treatment landscape for advanced renal cell carcinoma.

In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options for advanced renal cell carcinoma (RCC).

Survival is good for patients when renal cell carcinoma (RCC) is caught early, but options for advanced disease present challenges, explained Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.

Many times, renal cell carcinoma (RCC) is found incidentally, as a result of something else, said Alan Tan, MD, an assistant professor in the Division of Hematology, Oncology and Cell Therapy at Rush Medical College and the director of GU Medical Oncology.